- Home
- KAPA
KAPA
KAIROS PHARMA LTD
as 04-24-2025 4:00pm EST
Stocks
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | N/A | IPO Year: | 2024 |
| Target Price: | $8.33 | AVG Volume (30 days): | 149.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $4.00 | Next Earning Date: | 04-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest KAIROS PHARMA LTD News
KAPA Breaking Stock News: Dive into KAPA Ticker-Specific Updates for Smart Investing
Business Wire
10 hours ago
Kairos Pharma Ltd. Provides Letter to Stockholders
Business Wire
7 days ago
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
TipRanks
20 days ago
Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls
Business Wire
24 days ago
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
Newsfile
a month ago
CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105
Business Wire
a month ago
Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
Business Wire
a month ago
Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
Business Wire
2 months ago
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
Compare KAPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KAPA KAIROS PHARMA LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.